Full Breakdown
Tilray Brands Stock Surge Linked to Potential Marijuana Rescheduling
12/13/2025, 2:09:05 AM
Recent Stock Performance and Product Launch
Tilray Brands Inc. (NASDAQ: TLRY) experienced a significant surge in its stock price, rising 31.55% in after-hours trading on Thursday to reach $11.09. This increase follows the announcement of its new Amped Live Resin Liquid Diamond product line, which includes 1g 510 cartridges featuring strains such as Space Age CK and Blueberry DNTS. The product combines 80% Legit Live Resin with 20% Liquid Diamonds, aiming to deliver strain-specific terpenes and full-spectrum cannabinoids. The cartridges are currently available in Ontario and Alberta, with plans for national distribution in early 2026.
Impact of Potential Marijuana Rescheduling
The stock's rise is also attributed to a report from The Washington Post indicating that President Donald Trump is expected to issue an executive order to reclassify marijuana from Schedule I to Schedule III. This change would reduce regulatory burdens on marijuana businesses, allowing them to operate more similarly to prescription medications. While this move would not legalize marijuana outright, it would facilitate banking services and lessen tax obligations for marijuana companies, potentially increasing demand and sales for businesses like Tilray.
Market Context and Trading Metrics
Despite the recent gains, Tilray's stock is down 42.26% year-to-date but has rebounded 102.64% over the past six months. The company has a market capitalization of $9.49 billion, with a 52-week trading range of $3.51 to $23.20. As of Thursday, Tilray closed at $8.43, reflecting a 2.06% increase. The stock's momentum is noted to be in the 81st percentile, although it has a negative price trend across all time frames.
Criticism and Concerns
While the potential rescheduling of marijuana is seen as a positive development for Tilray and the broader cannabis industry, some analysts express skepticism. Despite the legalization of marijuana in Canada, where Tilray is based, the company has not turned a profit since 2018. Critics argue that regulatory changes in the U.S. may not necessarily translate to profitability for Tilray, given its historical financial performance.
Official Statements and Responses
A White House spokesperson indicated that no final decisions have been made regarding the marijuana rescheduling, suggesting that while discussions are ongoing, the outcome remains uncertain. The implications of such a decision could significantly impact the cannabis market, particularly for companies like Tilray.
Verbatim Quotes
- “President Trump just delivered an early Christmas gift to Tilray.” — Analyst, The Fool
- “This will set in motion a process to reduce the regulation of weed, such that it's treated much like "common prescription painkillers and other drugs," and less like drugs such as heroin or LSD.” — Analyst, The Fool
The developments surrounding Tilray Brands and the potential rescheduling of marijuana highlight a pivotal moment for the cannabis industry, with implications for market dynamics and regulatory frameworks.
